Antibody Therapies in Autoimmune Encephalitis

Area of Science:

• Neuroimmunology
• Neurology

Background:

• Autoimmune encephalitis (AE) involves immune attacks on the central nervous system.
• Anti-N-methyl-D-aspartate receptor encephalitis is a key example.
• Current AE immunotherapy relies on clinical experience and B cell-targeted antibodies.

Purpose of the Study:

• To review current and emerging monoclonal antibody (mAb) therapies for autoimmune encephalitis.
• To discuss novel therapeutic targets beyond traditional immunotherapy.

Main Methods:

• Review of existing literature and clinical practices in AE treatment.
• Discussion of various classes of monoclonal antibodies (mAbs).

Main Results:

• First-line AE therapy includes steroids, immunoglobulins, and plasma exchange.
• Second-line options include alkylating agents or B cell-targeting mAbs like rituximab.
• Emerging mAbs target B cells, IL-6, FcRn, and complement pathways.

Conclusions:

• Monoclonal antibodies represent a significant advancement in AE treatment.
• Future AE therapy may involve earlier or expanded use of targeted mAbs.
• The discussion covers mAbs targeting B cells, IL-6, FcRn, and complement.